Depleting circulating galectin-3 with therapeutic apheresis: a novel treatment for sepsis/AKI.
Ended Project Grant Awarded Last action
- Award ID
- R43GM130227
- Recipient
-
Eliaz Therapeutics, Inc. UEI Q7MDXXBML3P1
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $224,577
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Originally
- Place of performance
- Santa Rosa, CA 95401, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $224,577 |
Quick answers
Who received award R43GM130227?
R43GM130227 was awarded to Eliaz Therapeutics, Inc. by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2018.
How much is award R43GM130227 worth?
$224,577 has been obligated on R43GM130227.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award